Vetoquinol : Good Q3 sales with an acceleration at the organic level – Update / target price: € 85
>Q3: the “Essentiels” (51% of sales) continue to drive growth - Q3 revenues (€ 114.5m) rose by 14.3% and 18.9% at constant currency (cc) and by 12.7% l-f-l.Q3 2020 saw the consolidation of Drontal® and Profender®, whilst Clarion (Brazil) no longer has a scope effect (consolidation as of 15 April 2019).All regions reflected growth with organic growth rates of +4%, +16% and +29% respectively for Europe, the Americas and Asia Pacific/rest of the world. In ...V?toquinol is a global player in the animal health sector, serving both the livestock (cattle and pigs) and pet (dogs and cats) markets. Co. designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region, as an independent entity. Co. is also active in the therapeutic fields of anti-infectives, pain-inflammation and cardiology-nephrology treatment. As of Dec 31 2013, Co.'s product portfolio included brands such as Aurizon®, Epiphen®, Ipakitine®, Marbocyl®, Propalin®, Tolf?dine®, Tolfine®, Clavaseptin®, and Vetprofen®. Co.'s brands are V?toquinol, Tomlyn, and Evsco in the U.S.A. and Equistro for the horse range.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.